Isconova AB

Isconova AB is a biotechnology company focused on developing innovative vaccine adjuvants. Their products enhance vaccine effectiveness, supporting advancements in immunology and infectious disease control. Isconova AB, founded in 1999 in Uppsala, Sweden, specializes in vaccine adjuvant development. In November 2010, Isconova listed on the NASDAQ OMX First North exchange, with Innovation Kapital retaining a 45.

9% stake in the firm. The company has completed two deals, with the latest being on November 10, 2010. The total amount raised by Isconova is SEK 79. 220 mn through an IPO, which represents their entire funding to date.

Isconova AB develops proprietary vaccine adjuvants aimed at enhancing the immune response to vaccines. Their main offering includes a range of adjuvant formulations that support various vaccine candidates, thereby playing a critical role in the fight against infectious diseases. These products are designed to be used with a wide array of vaccines, from those targeting seasonal influenza to more complex vaccine formulations, facilitating more effective and robust immunizations. Isconova generates revenue primarily through the sale of its adjuvant products to pharmaceutical companies and research institutions.

The revenue model is typically based on contractual agreements, where clients pay for research collaborations and product development. This structured approach provides a stable income stream from both public and private sector partnerships, ensuring continuous funding for ongoing research and operational expenses. Isconova plans to leverage its IPO proceeds to accelerate the development of new adjuvant products targeting emerging infectious diseases. The company aims to expand its presence in international markets, particularly in North America and Europe, by 2023.

The recent funding will support ongoing research initiatives and bolster marketing efforts in these regions, enhancing their operational capabilities and client outreach.